Landscape Capital Management L.L.C. acquired a new position in Boston Scientific Corporation (NYSE:BSX – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 97,691 shares of the medical equipment provider’s stock, valued at approximately $4,169,000.
A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Renaissance Group LLC purchased a new position in shares of Boston Scientific in the fourth quarter worth about $28,064,000. Perigon Wealth Management LLC bought a new position in Boston Scientific in the 2nd quarter worth approximately $883,000. Y Intercept Hong Kong Ltd boosted its holdings in Boston Scientific by 148.8% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock worth $47,816,000 after buying an additional 670,060 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab grew its stake in Boston Scientific by 9.9% in the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock valued at $13,659,000 after buying an additional 28,961 shares in the last quarter. Finally, Meiji Yasuda America Inc bought a new stake in Boston Scientific during the 4th quarter valued at $4,708,000. 89.07% of the stock is owned by institutional investors.
Insider Buying and Selling
In related news, Director Edward J. Ludwig acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were bought at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the transaction, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David C. Habiger bought 2,100 shares of the stock in a transaction that occurred on Wednesday, August 5th. The stock was bought at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the purchase, the director directly owned 17,160 shares of the company’s stock, valued at $816,644.40. This represents a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have purchased 194,522 shares of company stock worth $9,385,210. Insiders own 0.34% of the company’s stock.
Analyst Ratings Changes
View Our Latest Analysis on Boston Scientific
Boston Scientific Price Performance
NYSE:BSX opened at $50.39 on Friday. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The stock has a fifty day moving average of $46.34 and a 200 day moving average of $57.86. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The firm has a market capitalization of $73.03 billion, a price-to-earnings ratio of 20.40, a P/E/G ratio of 1.08 and a beta of 0.56.
Boston Scientific (NYSE:BSX – Get Free Report) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same period in the prior year, the company earned $0.75 EPS. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, research analysts expect that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.
Boston Scientific declared that its Board of Directors has initiated a stock repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its shares are undervalued.
About Boston Scientific
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Featured Articles
- Five stocks we like better than Boston Scientific
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
